{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Lee SH"],"funding":["National Research Foundation of Korea (NRF)","National Research Foundation of Korea"],"pagination":["968-984"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC7937683"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["28(3)"],"pubmed_abstract":["Gallbladder carcinoma (GBC) exhibits poor prognosis due to local recurrence, metastasis, and resistance to targeted therapies. Using clinicopathological analyses of GBC patients along with molecular in vitro and tumor in vivo analysis of GBC cells, we showed that reduction of Dsg2 expression was highly associated with higher T stage, more perineural, and lymphatic invasion. Dsg2-depleted GBC cells exhibited significantly enhanced proliferation, migration, and invasiveness in vitro and tumor growth and metastasis in vivo through Src-mediated signaling activation. Interestingly, Dsg2 binding inhibited Src activation, whereas its loss activated cSrc-mediated EGFR plasma membrane clearance and cytoplasmic localization, which was associated with acquired EGFR-targeted therapy resistance and dec"],"journal":["Cell death and differentiation"],"pubmed_title":["Loss of desmoglein-2 promotes gallbladder carcinoma progression and resistance to EGFR-targeted therapy through Src kinase activation."],"pmcid":["PMC7937683"],"funding_grant_id":["2018R1A2B2006724","2017R1A5A2015385","2017R1D1A1B04034638","2013M3A9B6046566","2015M3A9D7029882"],"pubmed_authors":["Cho HS","Kim JM","Park JG","Huh YM","Lee SJ","Lee SH","Lee J","Cho YL","Han TS","Kim N","Kim JS","Min JK","Joo M","Bae KH","Yun HJ","Lee MS","Jo DY","Park YJ","Lee DG","Lee HJ","Jeon HJ"],"additional_accession":[]},"is_claimable":false,"name":"Loss of desmoglein-2 promotes gallbladder carcinoma progression and resistance to EGFR-targeted therapy through Src kinase activation.","description":"Gallbladder carcinoma (GBC) exhibits poor prognosis due to local recurrence, metastasis, and resistance to targeted therapies. Using clinicopathological analyses of GBC patients along with molecular in vitro and tumor in vivo analysis of GBC cells, we showed that reduction of Dsg2 expression was highly associated with higher T stage, more perineural, and lymphatic invasion. Dsg2-depleted GBC cells exhibited significantly enhanced proliferation, migration, and invasiveness in vitro and tumor growth and metastasis in vivo through Src-mediated signaling activation. Interestingly, Dsg2 binding inhibited Src activation, whereas its loss activated cSrc-mediated EGFR plasma membrane clearance and cytoplasmic localization, which was associated with acquired EGFR-targeted therapy resistance and dec","dates":{"release":"2021-01-01T00:00:00Z","publication":"2021 Mar","modification":"2026-05-07T18:49:03.739Z","creation":"2022-02-09T08:14:09.316Z"},"accession":"S-EPMC7937683","cross_references":{"pubmed":["32989241"],"doi":["10.1038/s41418-020-00628-4"]}}